Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review-Reference-Cited by-同舟云学术

Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review

Published:2020-02-14 Issue:4 Volume:18 Page:491-508
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Bouée-Benhamiche Elsa,Bousquet Philippe Jean,Ghabri Salah

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40258-020-00562-z.pdf

Reference53 articles.

1. Paris V. Cost of anticancer drugs: a challenge for health systems of OCDE countries. Bull Acad Natle Méd. 2019;202(5–6):989–1002.

2. Institut National du Cancer. Les cancers en France en 2018: l’essentiel des faits et des chiffres. Edition 2019. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Les-cancers-en-France-en-2018-L-essentiel-des-faits-et-chiffres-edition-2019. Accessed 04 Jun 2019.

3. Howard D, Bach P, Berndt E, Conti R. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.

4. Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, et al. EMA and NICE appraisal processes for cancer drugs: current status and uncertainties. Appl Health Econ Health Policy. 2018;16(4):429–32.

5. Megerlin F. Médicaments innovants onéreux: vers le paiement de résultats contractualisés? Revue Française des affaires sociales. 2018;3:129–46.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement;Value in Health;2024-07